ClinicalTrials.gg
Not yet recruitingNCT07492186BAL3HUpdated Mar 31, 2026

3-hour Versus 12-hour Double-balloon Catheter for Labor Induction

An interventional study of Cook® double-balloon catheter in Induction of Childbirth, sponsored by Centre Hospitalier de PAU. Not yet recruiting at 1 site in France. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-31.

Sponsored by Centre Hospitalier de PAU · Not applicable, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
280
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

This study aims to demonstrate that a 3-hour ultra-short cervical ripening protocol using a double-balloon catheter significantly reduces the induction-to-birth interval by at least 6 hours compared to the standard 12-hour protocol. The study evaluates whether this reduction can be achieved without increasing cesarean section rates or maternal-fetal risks

Read the detailed description

Scientific Justification: Labor induction affects 25% of pregnancies in France, with 70% requiring cervical ripening. While the 12-hour pose is standard, recent evidence suggests that shorter durations (6h) are effective but remain difficult to integrate into hospital workflows. Since the mechanical and physiological effects of the balloon are early phenomena, a 3-hour protocol could optimize bed management and patient comfort.

Strategy: Comparison between an experimental group (3-hour balloon pose followed by immediate active labor management regardless of Bishop score) and a control group (standard 12-hour balloon pose).

Follow-up: Participants are followed from the day of induction until hospital discharge (generally 2 to 10 days) to assess obstetric outcomes, neonatal safety, and maternal satisfaction.

02

Conditions studied

  • Induction of Childbirth
03

In context

Lead sponsor

Centre Hospitalier de PAU is the lead sponsor of 13 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years,
  • singleton pregnancy
  • ≥ 34 weeks of gestation,
  • cephalic presentation,
  • Bishop score \< 6,
  • healthy uterus,
  • standard indication for labor induction

Exclusion criteria

Exclusion Criteria:

  • Minor patients,
  • ruptured membranes,
  • twin pregnancy,
  • fetal malpresentation,
  • placenta previa,
  • previous uterine scar,
  • known fetal malformation
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
280 participants (estimated)

Study arms

  • Experimental
    3-hour pose

    3-hour pose of the Cook® double-balloon catheter

    Device: Cook® double-balloon catheter

  • Active comparator
    12-hour pose (standard care)

    12-hour pose of the Cook® double-balloon catheter (standard care)

    Device: Cook® double-balloon catheter

Interventions

  • DeviceCook® double-balloon catheter

    For both arms, the same double-balloon device is used. After the allocated time (3h or 12h) or spontaneous expulsion, active labor management is initiated, including early amniotomy and/or oxytocin administration

06

What researchers measure

Primary outcomes

  1. induction-to-birth interval reduction

    Time (in hours) between the effective initiation of labor induction (balloon insertion) and the birth of the child

    Time frame: balloon insertion and birth of the child

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Mar 2027; primary completion for Mar 2027, 0 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2026
First posted
Mar 25, 2026
StartEst.
Mar 1, 2027
Primary completionEst.
Mar 15, 2027
CompletionEst.
Mar 15, 2027
Last update
Mar 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07492186
Lead sponsor
Centre Hospitalier de PAU
Responsible party
Sponsor
First posted
Mar 25, 2026
Start date
Mar 1, 2027 (estimated)
Primary completion
Mar 15, 2027 (estimated)
Completion
Mar 15, 2027 (estimated)
Last update
Mar 31, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion